Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2024-08-05 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
国浩律师（上海）事务所关于北京星昊医药股份有限公司2023年股权激励计划调整事项之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding adjustments to a 2023 equity incentive plan of Beijing Xinghao Pharmaceutical Co., Ltd. It references various legal and regulatory frameworks related to securities law, stock incentive plans, and corporate governance. The document details the approval and authorization process of the equity incentive plan adjustments, including board and shareholder meetings, disclosures, and compliance with relevant laws and regulations. It does not contain financial statements or earnings data, nor is it a transcript, presentation, or announcement of voting results. It is a legal opinion related to corporate governance and management decisions about equity incentives. Therefore, it fits best under the category of Regulatory Filings (RNS), as it is a compliance/legal document that does not fit other specific categories like Annual Report, Earnings Release, or Management Reports.
2024-08-05 Chinese
关于调整2023年股权激励计划相关事项的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding adjustments to its 2023 equity incentive plan. It details board and supervisory committee meetings, approvals, and specific adjustments to stock option prices and restricted stock repurchase prices following a dividend distribution. The document is a formal disclosure of changes to the equity incentive plan terms, including legal opinions and supervisory approvals. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a call transcript, earnings release, or a proxy solicitation. The content focuses on management decisions and disclosures related to stock-based compensation plans, which aligns with announcements about management or board decisions. Given the nature of the content—announcement of adjustments to the equity incentive plan and related approvals—the best fitting category is Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into more specific categories like Remuneration Information or Board/Management Information, since it is about plan adjustments rather than personnel changes or compensation details per se. The document length is 4026 characters, which is relatively short and consistent with an announcement rather than a full report.
2024-08-05 Chinese
第七届监事会第十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of an agenda item related to the adjustment of the 2023 equity incentive plan. It references another announcement (公告编号：2024-071) for detailed content. The document is short (807 characters) and serves as a formal meeting resolution announcement rather than a full report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report publication announcement since it contains substantive meeting resolution content. The document fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like MANG (board changes) or CAP (capital updates).
2024-08-05 Chinese
独立董事候选人声明与承诺
Board/Management Information Classification · 95% confidence The document is a statement and commitment by an independent director candidate for a company's board, detailing qualifications, independence criteria, and legal compliance. It does not contain financial data, audit results, or report content. It is not an announcement of voting results or a proxy solicitation but rather a declaration related to board/management information. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on director candidacy, not a full report or announcement of a report publication.
2024-08-05 Chinese
回购进展情况公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement regarding the progress of a share repurchase (buyback) plan by Beijing Xinghao Pharmaceutical Co., Ltd. It details the repurchase scheme, including the purpose, pricing, quantity, funding source, and implementation timeline. It also reports the status of the repurchase as of a certain date, stating that no shares have been repurchased yet. The document is relatively short (1870 characters) and focuses on the update of the share buyback activity rather than presenting financial statements or detailed financial analysis. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares (share repurchase/issuance).
2024-08-01 Chinese
关于拟减少注册资本通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Beijing Xinghao Pharmaceutical Co., Ltd. regarding a proposed reduction in registered capital through a share repurchase plan. It includes details about the board and shareholder meetings approving the plan, legal references, and instructions for creditors to submit claims within a specified period. The content focuses on notifying creditors about the capital reduction and share repurchase, not on presenting financial results or detailed financial data. The document length is short (1364 characters) and is an official notice rather than a report or detailed financial statement. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding share repurchases and capital changes.
2024-07-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.